Hemophilia B mouse (B6.129P2-F9tm1Dws) with predecessor vector AMT-060: dose-dependent liver transduction, hFIX protein and activity
“At 4 weeks following intravenous (IV) administration of 5x1011 to 2.3x1014 gc/kg of AMT-060 in the B6.129P2-F9tm1Dws mouse model of Hemophilia B, dose-dependent increases in vector transduction in the liver, plasma hFIX protein levels, and plasma hFIX activity were observed.”
✓ VerifiedFDA summary basis for approval, p. 10Source ↗
Why that model
NHPs considered most relevant species for nonclinical efficacy and safety, as natural AAV hosts
“From the pharmacokinetic point of view, non-human primates were the most relevant species for nonclinical efficacy and safety studies, as natural hosts for AAVs.”
Adequate evidence of efficient hepatocyte transduction and dose-dependent, durable hFIX activity in mice and monkeys
“Overall, the primary pharmacodynamic studies provided adequate evidence that murine and monkey hepatocytes are efficiently transduced by etranacogene dezaparvovec and produce hFIX dosedependently, enabling sustained and durable hFIX activity levels.”
WAS-deficient mice transplanted with WAS LVV-transduced murine Lin- BM cells: increased B cells, platelets, granulocytes; improved T, B and DC function